Back to today’s briefing

Story perspectives

Moderna Announces $2 Billion Zero-Interest Convertible Notes Offering

8/27/2026

38 8 Full Breakdown

Summary

Story summary

Moderna announced a $2 billion senior convertible note offering to fund oncology.
The notes bear no interest and mature in 2032.
The offering permits up to $300 million of additional issuance.
Proceeds will fund hedging and support oncology expansion.
Analyst William Blair valued Intismeran’s U.S. wholesale price at $475,000 per patient in the United States.

History

Historical Context

Novartis’s imatinib mesylate (Gleevec) earned FDA approval in May 2001, converting chronic myeloid leukemia into a chronic condition and proving the first targeted cancer therapy. The 2013 Indian Supreme Court’s rejection of Gleevec’s patent highlighted ongoing global disputes over drug pricing and access, reflecting the broader impact of the drug’s market success.

1 of 2

Story summary

Moderna announced a $2 billion senior convertible note offering to fund oncology.
The notes bear no interest and mature in 2032.
The offering permits up to $300 million of additional issuance.
Proceeds will fund hedging and support oncology expansion.
Analyst William Blair valued Intismeran’s U.S. wholesale price at $475,000 per patient in the United States.

1 / 2